Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.89 and traded as low as $3.95. Bolt Biotherapeutics shares last traded at $4.21, with a volume of 21,880 shares trading hands.

Wall Street Analysts Forecast Growth

BOLT has been the subject of several research reports. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bolt Biotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $34.67.

Bolt Biotherapeutics Price Performance

The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. The company’s fifty day moving average price is $4.48 and its 200 day moving average price is $4.89. The company has a market capitalization of $8.08 million, a P/E ratio of -0.26 and a beta of 1.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. As a group, sell-side analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Institutional Trading of Bolt Biotherapeutics

Large investors have recently modified their holdings of the stock. T3 Companies LLC bought a new stake in Bolt Biotherapeutics during the fourth quarter worth $208,000. Renaissance Technologies LLC raised its holdings in shares of Bolt Biotherapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter worth $112,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth $89,000. Finally, Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth $85,000. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.